NUVL
Nuvalent, Inc.
$123.96
+0.00%
2026-07-21
About Nuvalent, Inc.
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Key Fundamentals
Forward P/E
-29.99
EPS (TTM)
$-6.06
ROE
-41.2%
Profit Margin
0.0%
Price/Book
8.32
Beta
1.14
Market Cap
$9.80B
Avg Volume (10D)
1.7M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$123.99
60D Low
$87.30
Avg Volume
2.2M
Latest Close
$123.96
Get breakout alerts for NUVL
Sign up for Breakout Scanner to receive daily notifications when NUVL triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Nuvalent, Inc. (NUVL) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors NUVL daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. NUVL operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.